Caris Life Sciences, Inc. (CAI)
CAI Stock Price Chart
Explore Caris Life Sciences, Inc. interactive price chart. Choose custom timeframes to analyze CAI price movements and trends.
CAI Company Profile
Discover essential business fundamentals and corporate details for Caris Life Sciences, Inc. (CAI) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
18 Jun 2025
Employees
1.85k
CEO
David Dean Halbert
Description
Caris Life Sciences, Inc. operates as a leading "TechBio" firm, harnessing artificial intelligence to deliver comprehensive molecular profiling services to clients both in the United States and internationally. The company is dedicated to transforming medical care by innovating and bringing to market advanced solutions that leverage molecular data and sophisticated machine learning algorithms. Its extensive suite of molecular diagnostic offerings includes MI Profile, a specialized solution analyzing tissue samples, and Caris Assure, a blood-based test designed for cancer treatment applications. Furthermore, Caris provides research and development support to biopharmaceutical customers, encompassing laboratory delivery, strategic data insights, and dedicated research initiatives. Established in 2008, the company maintains its corporate headquarters in Irving, Texas.
CAI Financial Timeline
Browse a chronological timeline of Caris Life Sciences, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 5 Aug 2026
EPS estimate is -$0.01, while revenue estimate is $238.11m.
Earnings released on 7 May 2026
EPS came in at -$0.00 surpassing the estimated -$0.02 by +92.53%, while revenue for the quarter reached $216.17m , beating expectations by +3.23%.
Earnings released on 26 Feb 2026
EPS came in at $0.28 surpassing the estimated -$0.02 by +1.50k%, while revenue for the quarter reached $292.89m , beating expectations by +21.84%.
Earnings released on 5 Nov 2025
EPS came in at $0.08 surpassing the estimated -$0.08 by +200.00%, while revenue for the quarter reached $216.83m , missing expectations by -22.82%.
Earnings released on 12 Aug 2025
EPS came in at -$0.54 falling short of the estimated -$0.21 by -157.14%, while revenue for the quarter reached $181.40m , beating expectations by +31.76%.
CAI Stock Performance
Access detailed CAI performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
